CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00068783
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:35:22.030211+00:00
- Published At
- 2013-02-28T00:00:00+00:00
- Record Updated At
- 2013-02-28
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Recurrent Neuroendocrine Carcinoma of the Skin", "Stage II Neuroendocrine Carcinoma of the Skin", "Stage III Neuroendocrine Carcinoma of the Skin"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2013-02-28"- protocolSection.identificationModule.nctId
"NCT00068783"- protocolSection.identificationModule.officialTitle
"A Phase II Trial of STI-571/Imatinib (Gleevec\u00ae) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.